This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Hyperimmunoglobulin E [IgE] syndrome / HIES / Job syndrome고면역글로불린E증후군 (욥증후군)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D82.4 (hyperimmunoglobulin E syndrome) | OMIM: 147060 (AD-HIES, STAT3) / 243700 (AR-HIES, DOCK8) | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsHyper-IgE syndrome, Job syndrome, Buckley syndrome (hyper-IgE, recurrent pneumonia, eczema), AD-HIES (STAT3 deficiency), AR-HIES (DOCK8 deficiency), Hyper-IgE recurrent infection syndrome
C. Adult onsetLikelihood of first onset in adulthood moderate — first symptoms commonly appear in childhood with infantile eczema and recurrent skin abscesses, but mild AD-HIES is sometimes first diagnosed in adulthood with recurrent pneumonia or fractures (osteoporosis); thymoma-associated acquired HIES occurs in adults.
1. History1966 Davis and colleagues described "Job syndrome" (triad of skin abscesses, pneumonia, erythema) → 1972 Buckley and colleagues linked it to hyper-IgE → 2007 STAT3 variants discovered → 2009 DOCK8 variants (AR-HIES) discovered.
2. CausesAD-HIES: loss-of-function variants of the STAT3 gene (17q21.31). AR-HIES: DOCK8 gene (9p24.3), rarely TYK2, PGM3, or ZNF341 variants. STAT3 deficiency → abnormal IL-6/IL-10/IL-21 signaling → reduced Th17 → susceptibility to fungi and staphylococci.
3. GeneticsAD-HIES: autosomal dominant, STAT3 (17q21.31), loss of function (dominant negative). AR-HIES: autosomal recessive, DOCK8 (9p24.3). De novo variants common (about 60% of AD-HIES).
4. General epidemiologyAbout 1:100,000~1:500,000. AD-HIES more common; males and females equally affected. Worldwide distribution; no particular ethnic predilection. Rare in Korea, with limited separate epidemiological statistics.
5. PathophysiologySTAT3 deficiency → impaired Th17 cell differentiation → reduced IL-17 → impaired neutrophil recruitment and barrier defense. At the same time, Th2 predominance → IgE overproduction. Abnormal STAT3 signaling in bone and connective tissue → osteoporosis and aneurysms. DOCK8 deficiency → impaired migration and cytotoxicity of T/B/NK cells.
6. SymptomsAD-HIES: recurrent staphylococcal skin abscesses (cold abscesses), recurrent pneumonia → emphysema/bronchiectasis, neonatal eczema, characteristic facies, retained primary teeth, osteoporosis and scoliosis, cerebrovascular abnormalities. AR-HIES: severe herpesvirus infections, allergies, malignancies.
7. SignsSerum IgE >2,000 IU/mL (often tens of thousands to hundreds of thousands); eosinophilia; characteristic facies (coarse face, broad nose, deep-set eyes); lung CT: emphysema, bronchiectasis, cavitation; typical NIH clinical score (NIH scoring system) ≥40 points.
8. ScreeningSerum IgE quantification (when hyper-IgE is suspected); eosinophil count; calculation of the NIH HIES clinical score; children with a family history: STAT3/DOCK8 genetic testing. Screening by Th17 cell fraction (flow cytometry).
9. DiagnosisSerum IgE quantification; NIH clinical score; STAT3/DOCK8 gene sequencing; Th17 cell fraction; STAT3 phosphorylation functional assay; lung CT (assessment of lung structure); skin biopsy (eosinophilic infiltration).
10. TreatmentAD-HIES: prophylactic TMP-SMX/antistaphylococcal antibiotics, antifungals, IVIG (when accompanied by hypogammaglobulinemia); HSCT (severe cases or AR-HIES). AR-HIES: HSCT (effective for immune correction). Skin care, management of pulmonary complications (surgical resection of emphysema).
11. PrognosisAD-HIES: survival for a considerable period possible with infection management; pulmonary complications (bronchiectasis, aspergillosis) and vascular complications are the main causes of death. AR-HIES: malignancies and viral infections determine prognosis. Immune improvement in AR-HIES after HSCT.
12. PreventionGenetic counseling (for AD and AR respectively); continued prophylactic antibiotics and antifungals; skin barrier care; regular imaging for pulmonary complications; osteoporosis prevention (calcium and vitamin D, bone density measurement); malignancy screening (AR-HIES).
13. ReferencesDavis SD et al. Job's Syndrome — Recurrent "cold" staphylococcal abscesses … and 9 other papers

1. History

The history of hyperimmunoglobulin E syndrome (HIES) begins with a 1966 case report in which the American pediatricians Sheldon Davis, Edward Henderson, and Maxfield Smith named the condition 'Job's syndrome,' conveying that, like Job as described in the Bible, the patients' skin was never free of boils. They published in The Lancet the unusual clinical pattern of two red-haired girls with recurrent staphylococcal skin abscesses from infancy, recurrent pneumonia, and persistent eczematous skin rash. Although the immune mechanism was not known at the time, this report later became the foundation of HIES research.

In 1972, Rebecca Buckley and colleagues described a similar clinical picture in two boys and were the first to report that extreme elevation of serum IgE concentration is characteristic of this syndrome. In their patients, IgE reached thousands of times the normal level, and this finding led to the disease being renamed 'Hyper-IgE syndrome (HIES).' In the 1980s~90s, large cohort studies centered at the NIH (US National Institutes of Health) gradually revealed a spectrum beyond the clinical triad, comprising recurrent infections, hyper-IgE, eosinophilia, characteristic facies, and skeletal and connective tissue abnormalities, and the NIH clinical scoring system was developed and began to be used as a diagnostic aid.

The molecular genetic cause was identified in 2007. The group of Steven Holland and the group of Professor Bodo Grimbacher each simultaneously published loss-of-function variants (dominant negative) of the STAT3 (signal transducer and activator of transcription 3) gene as the cause of autosomal dominant HIES (AD-HIES). This discovery was a landmark achievement that revealed the central role of the STAT3-IL-17 pathway in the pathophysiology of HIES and opened a new chapter in HIES research. In 2009, research groups in Japan and the US independently reported variants of the DOCK8 (dedicator of cytokinesis 8) gene as the cause of autosomal recessive HIES (AR-HIES), and AR-HIES was confirmed to have clinical features distinct from AD-HIES (susceptibility to viral infections, increased risk of malignancy, neurological complications). Subsequently, additional genes causing HIES-like phenotypes, such as TYK2 deficiency, PGM3 deficiency, and ZNF341 variants, were discovered, expanding the molecular classification system of HIES.

HIES is currently classified as ICD-10 D82.4 and is used as a concept encompassing AD-HIES (STAT3 deficiency) and AR-HIES (DOCK8 deficiency, etc.). Because the two types differ considerably in clinical features, mode of inheritance, pathophysiology, and treatment strategy, accurate subtype distinction through genetic diagnosis is clinically important.

2. Causes

HIES is genetically divided into two main subtypes. Autosomal dominant HIES (AD-HIES) is caused by pathogenic variants of the STAT3 gene (long arm of chromosome 17, 21.31, 17q21.31). The STAT3 gene encodes the STAT3 (Signal Transducer and Activator of Transcription 3) protein, a key transcription factor of the Janus kinase (JAK)-STAT signaling pathway. The STAT3 variants identified in AD-HIES are loss-of-function dominant negative variants, in which the mutant STAT3 protein interferes with the function of normal STAT3 protein, causing loss of function beyond haploinsufficiency. Because signaling by various cytokines, such as IL-6, IL-10, IL-21, IL-23, and IFN-γ, is mediated through STAT3, STAT3 deficiency affects a wide range of immune and non-immune cell functions.

The most common cause of autosomal recessive HIES (AR-HIES) is biallelic variants of the DOCK8 (dedicator of cytokinesis 8) gene (short arm of chromosome 9, 24.3, 9p24.3). DOCK8 mediates actin cytoskeletal remodeling through CDC42 guanine nucleotide exchange factor (GEF) activity and is essential for the migration, cell junctions (immune synapse formation), and cytotoxic function of T cells, B cells, and NK cells. In DOCK8 deficiency, the functions of these cells are globally impaired. Rare causes of AR-HIES reported include variants of TYK2 (tyrosine kinase 2, related to IL-12 receptor signaling), PGM3 (phosphoglucomutase 3, N-glycosylation defects), and ZNF341 (a transcriptional regulator of STAT3).

About 60% of AD-HIES is caused by de novo variants, and often there is no family history. The remaining 40% is transmitted within families in an autosomal dominant manner. The most common types of STAT3 gene variants are missense variants concentrated in the DNA-binding domain (DBD) or SH2 domain, and these variants exert a dominant negative effect. DOCK8 variants are mainly deletions (including large exon deletions), nonsense variants, and frameshift variants, resulting in complete loss of the protein.

3. Genetics

HIES is divided into two main subtypes according to the mode of inheritance. AD-HIES (OMIM #147060) follows autosomal dominant inheritance and is due to STAT3 gene (17q21.31) variants, and AR-HIES (OMIM #243700) follows autosomal recessive inheritance and is mainly caused by DOCK8 gene (9p24.3) variants.

In AD-HIES, STAT3 consists of 24 exons, and variants are concentrated mainly in the SH2 domain (exons 12~15) and the DNA-binding domain (exons 16~19). These variants act in a dominant negative manner: mutant STAT3 forms heterodimers with normal STAT3 protein and suppresses the nuclear transcriptional activity of normal STAT3. Therefore, even with one normal allele, about 75% or more of functional STAT3 activity may be lost. Because the proportion of de novo variants is high (about 60%), many cases arise without a family history, and clinical recognition for early diagnosis is important.

In AR-HIES, DOCK8 is a large gene consisting of 48 exons, and variants are distributed sporadically throughout the gene. Because large exon deletions are common, some variants may not be detected by standard Sanger sequencing, and copy number variant (CNV) analysis by CGH microarray (chromosomal microarray) or NGS is needed. When both parents are carriers, the chance of being affected is 25%.

In genetic counseling for AD-HIES, it is explained that each child of an affected parent has a 50% chance of being affected, and that with de novo variants the risk for siblings is low (considering the possibility of germline mosaicism), but each child of the affected patient has a 50% risk of being affected. For AR-HIES, counseling covers the 25% chance that each child of carrier parents is affected and the options of PGT/prenatal diagnosis. For both subtypes, appropriate treatment planning (particularly determining the indication for HSCT in AR-HIES) becomes possible after genetic confirmation.

4. General epidemiology

HIES is estimated to be a rare disease with a worldwide frequency of 1 per 100,000–500,000 births. The exact incidence is not well established, but hundreds to thousands of patients have been reported worldwide. Data on tens to hundreds of patients have been accumulated in large single-center registry studies such as the NIH HIES cohort. AD-HIES (STAT3 variants) accounts for a larger proportion than AR-HIES (DOCK8 variants).

There is no sex difference (autosomal inheritance); males and females are equally affected. No predilection for particular ethnic groups or regions has been reported, but AD-HIES due to de novo variants occurs sporadically in all ethnic groups worldwide. AR-HIES incidence may be relatively higher in populations where consanguineous marriage is common. Occurrence in Korea is also very rare, mainly at the level of a few case reports, and there are no systematic epidemiological data.

HIES typically presents with first symptoms (eczema, skin abscesses, recurrent pneumonia) from infancy to childhood, but some patients with mild AD-HIES remain undiagnosed until adulthood and are first identified through recurrent pneumonia or fractures (osteoporosis). AR-HIES patients tend to develop severe infections earlier, in infancy to childhood. The NIH clinical scoring system (maximum 100 points; ≥40 points strongly suggests HIES) is used as a standardized clinical diagnostic aid.

5. Pathophysiology

The core pathophysiology of AD-HIES (STAT3 deficiency) stems from impaired Th17 cell differentiation. Normally, cytokines such as IL-6, IL-21, and IL-23 activate STAT3 to induce expression of RORγt (RAR-related orphan receptor gamma t), a transcription factor essential for Th17 cell differentiation. In AD-HIES patients with loss of STAT3 function, this process is markedly impaired, so very few Th17 cells are generated. Th17 cells secrete IL-17A, IL-17F, and IL-22, stimulating neutrophil recruitment and antimicrobial peptide production at the epithelial barriers of the skin, lung, and gut. Deficiency of Th17/IL-17 signaling markedly reduces defense against Staphylococcus aureus and fungi (Candida, Aspergillus) in the skin and lungs. This is the fundamental reason why staphylococcal cold skin abscesses and pneumonia recur in AD-HIES patients.

The second major mechanism of STAT3 deficiency is Th2 predominance and IgE overproduction. STAT3 indirectly regulates STAT6 activation via IL-4 signaling; in STAT3 deficiency this balance is disrupted, so Th2 differentiation and IL-4 production become relatively enhanced, and as a result IgE class switching in B cells increases and serum IgE rises extremely. Dysfunction of memory B cells and regulatory B cells also contributes to persistent IgE overproduction. The high-IgE environment aggravates eczema through mast cell activation and also contributes to IgE-mediated inflammatory responses to staphylococcal toxins.

The non-immune abnormalities of AD-HIES (skeletal, connective tissue, and vascular abnormalities) are also explained by loss of STAT3 function. Because STAT3 is also involved in regulating the differentiation and function of osteoblasts and osteoclasts, STAT3 deficiency causes abnormal bone turnover, resulting in osteoporosis, retained primary teeth (delayed permanent teeth eruption), scoliosis, and a characteristic facial appearance. STAT3 is also expressed in vascular smooth muscle cells and endothelial cells and contributes to maintaining vascular structure; its deficiency leads to vascular complications such as cerebral aneurysms and coronary artery abnormalities.

In AR-HIES (DOCK8 deficiency), the main mechanism is loss of DOCK8's CDC42-activating function → impaired actin cytoskeleton reorganization → poor migration of T cells and NK cells and poor immune synapse formation → reduced cytotoxic function. In particular, DOCK8 deficiency in B cells leads to impaired class switching and somatic hypermutation, reducing antibody diversity, while in T cells the ability to eliminate cells infected with viruses such as EBV/HPV is reduced, increasing the risk of severe viral infections and malignancies (lymphoma, HPV-related squamous cell carcinoma).

6. Symptoms

The clinical symptoms of HIES differ in part by subtype (AD-HIES vs AR-HIES), and understanding the characteristic symptoms of each subtype is important for diagnosis and treatment.

Main symptoms of AD-HIES (STAT3 deficiency)

Recurrent staphylococcal cold skin abscesses (cold abscess) are the most characteristic feature. Unlike ordinary bacterial infections, abscesses form deep in the skin with little or no inflammatory response such as redness, warmth, or tenderness (cold abscess). This is because the inflammatory response is suppressed due to the lack of IL-17-mediated neutrophil recruitment. Recurrent pneumonia: pneumonia caused by S. aureus, H. influenzae, Klebsiella, etc. recurs, and cumulative lung parenchymal damage leads to pneumatoceles, bronchiectasis, and bronchopleural fistulas. Once fungi such as Aspergillus colonize the pneumatoceles, eradication is very difficult. Neonatal eczematous rash: erythematous papules and eczematous rash appear on the face within the first few weeks after birth and later spread to the whole body.

Non-immune features (specific to AD-HIES): A characteristic facial appearance (coarse face, broad nose, deep-set eyes, broad forehead) becomes evident after adolescence. Retained primary teeth: primary teeth do not shed normally, delaying eruption of permanent teeth. A double row of teeth is observed. Osteoporosis and fractures: fractures occur even with minor trauma, accompanied by scoliosis. Cerebrovascular abnormalities (aneurysms, lacunar infarct) may be found in adulthood.

Main symptoms of AR-HIES (DOCK8 deficiency): severe susceptibility to herpesviruses (HSV, VZV, CMV, EBV, HPV) → disseminated varicella, severe herpes simplex, EBV-associated lymphoproliferative disease. Recurrent cutaneous viral infections (molluscum contagiosum, extensive warts). Malignancies: increased risk of HPV-related squamous cell carcinoma and lymphoma. Neurological complications (cerebral vasculitis, stroke). Non-immune symptoms (skeletal and vascular abnormalities) are rare compared with AD-HIES.

7. Signs

The physical signs and laboratory findings of HIES are central to establishing diagnostic criteria.

Extreme elevation of serum IgE is the most important laboratory finding. In HIES, serum IgE is generally ≥2,000 IU/mL, and elevations to tens of thousands to hundreds of thousands of IU/mL are common. However, HIES cannot be diagnosed by IgE alone; high IgE can also occur in atopic dermatitis, allergy, parasitic infection, Omenn syndrome, etc., so the clinical context is important. Eosinophilia is often present, with an increased absolute eosinophil count in peripheral blood.

NIH HIES clinical scoring system: points are assigned to each clinical feature (cold abscess, pneumonia, pneumatocele, eczema, facial abnormality, retained primary teeth, fractures, scoliosis, hyperextensible joints, septic arthritis, otitis media, oral candidiasis, IgE level, eosinophil count) and summed; a score of ≥40 points indicates a high likelihood of HIES.

Immunological findings: a marked reduction (close to zero) in the Th17 cell fraction (flow cytometry, CD4+CD161+CD196+ or intracellular IL-17 staining) is a highly specific finding of STAT3-variant AD-HIES. T-cell and B-cell counts are generally within the normal range, but T-cell and NK-cell counts may be reduced in AR-HIES. Serum IgG, IgA, and IgM are mostly normal, but hypogammaglobulinemia is sometimes present in AR-HIES. STAT3 phosphorylation function testing (pSTAT3 measurement after cytokine stimulation, flow cytometry) confirms poor STAT3 activation.

Imaging findings: pneumatoceles, bronchiectasis, and cavitation are characteristic on chest CT. Fungal colonization within pneumatoceles (aspergilloma) is sometimes observed. Osteoporosis on bone densitometry (DEXA). Cerebrovascular abnormalities or lacunar infarct on brain MRI.

8. Screening

There is no systematic newborn screening program for HIES, but stepwise screening based on the clinical presentation is possible.

IgE measurement-based screening: serum IgE is measured in children with recurrent skin abscesses, recurrent pneumonia, or neonatal eczema, and if ≥2,000 IU/mL, HIES is actively considered in the differential. Serum IgE measurement is inexpensive and rapid and effective for initial screening. However, IgE varies with age, and in infancy IgE may be low even in affected children, so repeated measurement is recommended.

NIH HIES score calculation: clinical features are systematically assessed, and a score of ≥40 points is judged to indicate a high likelihood of HIES and leads to detailed workup. This scoring system is useful for judging the clinical diagnostic likelihood before genetic testing.

Th17 fraction screening: the Th17 cell fraction among peripheral blood CD4+ T cells is measured by flow cytometry; near-absence of Th17 cells (CD4+IL-17+ < 0.1%) in STAT3-variant AD-HIES is a specific marker. Th17 reduction is also seen in DOCK8-deficient AR-HIES.

Children with a family history: if a parent or sibling is affected, targeted testing of the STAT3 gene (AD-HIES) or DOCK8 gene (AR-HIES) is performed early after birth to determine whether the child is affected. In this case, early diagnosis → early initiation of prophylactic anti-infective therapy is possible.

9. Diagnosis

Diagnosis of HIES proceeds in stages of clinical score assessment, immune function testing, and genetic confirmation.

Step 1: clinical assessment: diagnostic likelihood is assessed by the combination of the NIH HIES clinical score (≥40 points) and serum IgE (≥2,000 IU/mL). Confirming the three cardinal signs of cold abscess, recurrent pneumonia, and eczema is important, and in adults a history of retained primary teeth, pneumatoceles, and osteoporosis are also important clues.

Step 2: immune function testing: quantification of serum immunoglobulins (IgG, IgA, IgM, IgE), peripheral blood T/B/NK cell fractions (flow cytometry), Th17 cell fraction measurement, STAT3 phosphorylation function testing (flow cytometry: pSTAT3 expression after IL-6/IL-10/IFN-γ stimulation). Absolute eosinophil count, CBC. NK-cell degranulation function (may be reduced in AR-HIES).

Step 3: genetic testing: sequencing of the STAT3 gene (17q21.31, exons 1–24) is performed first, and if negative, the DOCK8 gene (9p24.3, exons 1–48, including CNV analysis) is tested. DOCK8 deletions may in some cases be detectable only by CGH microarray or NGS CNV analysis. If no variant is found, TYK2, PGM3, and ZNF341 sequencing is considered.

Step 4: ancillary tests: chest CT (assessment of pneumatoceles, bronchiectasis, cavitation), bone densitometry (DEXA), dental examination (to confirm retained primary teeth), brain MRI (cerebrovascular abnormalities), and cardiovascular CT/MRA (aneurysms) are performed depending on the clinical situation.

Differential diagnosis: differentiation is needed from atopic dermatitis (IgE elevation but no recurrent bacterial infections or skeletal abnormalities), Omenn syndrome (IgE elevation + SCID phenotype), Wiskott-Aldrich syndrome (thrombocytopenia + eczema), Netherton syndrome (skin dysplasia + IgE elevation), and Omenn syndrome.

10. Treatment

Treatment of HIES is individualized according to subtype (AD vs AR), severity of immunodeficiency, and presence of complications.

Prophylactic anti-infective therapy (main pillar of AD-HIES treatment): TMP-SMX (trimethoprim-sulfamethoxazole) prophylaxis is standard, simultaneously preventing S. aureus and Pneumocystis. If MRSA is a concern, clindamycin or doxycycline is considered as an alternative. Antifungal prophylaxis (itraconazole or voriconazole) prevents Aspergillus infection. When infection occurs, aggressive antibiotic treatment and surgical drainage (cold abscess) are performed from the outset.

IVIG: regular IVIG administration in HIES patients with hypogammaglobulinemia (especially AR-HIES). Effective in reducing recurrent bacterial infections.

HSCT (hematopoietic stem cell transplantation): in AR-HIES (DOCK8 deficiency), HSCT markedly improves immune function and reduces the risk of viral infections and malignancies, and successful outcomes have been reported in multicenter cohorts. The role of HSCT in AD-HIES (STAT3 deficiency) is less established, and it is mainly considered when lymphoma develops or there are severe recurrent infections. The non-immune complications of STAT3 deficiency (skeletal and vascular) are not corrected by HSCT.

Management of pulmonary complications: when Aspergillus colonization develops within pneumatoceles, surgical resection or long-term antifungal therapy is required. When bronchiectasis has progressed, airway secretion management (postural drainage, inhalation therapy) is important.

Skin and eczema management: skin barrier management with moisturizers, topical steroids, and topical calcineurin inhibitors (tacrolimus ointment). Dilute bleach baths to reduce colonization by resident staphylococci on the skin. Osteoporosis: calcium and vitamin D supplementation, and bisphosphonate treatment if needed.

11. Prognosis

The prognosis of HIES differs greatly depending on subtype and the occurrence of complications. Patients with AD-HIES (STAT3 deficiency) can survive into adulthood with aggressive infection prevention and treatment, and a substantial number survive for several decades or more. However, as lung structural destruction from recurrent pneumonia (bronchiectasis, pneumatoceles, bronchopleural fistula) accumulates, lung function gradually declines. Aspergillus colonization within pneumatoceles and invasive pulmonary aspergillosis are major life-threatening complications. Cerebrovascular complications (aneurysm rupture, stroke) are also important causes of death.

Compared with AD-HIES, AR-HIES (DOCK8 deficiency) may have a poorer prognosis because severe viral infections develop at an earlier age and the risk of malignancies (lymphoma, HPV-related cancers) is higher. Without HSCT, many patients do not reach adulthood. Several cohort studies have confirmed that after HSCT, immune function improves significantly and the frequency of viral infections and the risk of malignancy decrease. The 5-year survival rate after HSCT is reported to be about 70–80%.

Overall, the keys to improving the prognosis of HIES are early diagnosis, continuous prophylactic anti-infective therapy, regular assessment of lung function, management of skeletal complications, and early HSCT planning in AR-HIES.

12. Prevention

Prevention of HIES consists of genetic prevention and prevention of complications.

Primary prevention (genetic prevention): in AD-HIES, 50% of the children of an affected parent may be affected, so genetic counseling is provided when planning pregnancy. Affected embryos/fetuses can be identified by PGT (preimplantation genetic testing) or prenatal diagnosis (CVS/amniocentesis). Primary prevention is difficult for AD-HIES due to de novo variants, but early genetic testing of the children of affected patients allows preventive measures to be started early. In AR-HIES, the 25% chance of being affected from carrier parents is explained, and PGT/prenatal diagnosis is offered.

Secondary prevention (prevention of complications): TMP-SMX and antifungal prophylaxis are started immediately upon diagnosis to prevent staphylococcal abscesses, Pneumocystis pneumonia, and Aspergillus infection. Skin hygiene care (bleach baths, moisturizers, topical antibacterial/antifungal agents) minimizes skin infections and eczema. After recurrent pneumonia, lung CT is used to detect pneumatoceles and bronchiectasis early and manage them aggressively. Calcium and vitamin D supplementation and regular bone densitometry (DEXA) prevent osteoporosis and reduce fracture risk. In AR-HIES, HSCT is performed early, before malignancy or severe viral infection develops.

Tertiary prevention (suppression of long-term complications): regular chest CT (monitoring of pulmonary complications), cerebrovascular imaging (MRI/MRA, aneurysm surveillance), dermatological examination (malignancy screening, especially HPV-related cancers in AR-HIES), endocrine evaluation (bone metabolism). Long-term prophylactic anti-infectives are maintained, and infectious episodes are responded to promptly. Collaborative care by a multidisciplinary team (immunology, infectious diseases, pulmonology, dermatology, orthopedics, dentistry, neurology) is required throughout life.


13. References

  1. Davis SD, Schaller J, Wedgwood RJ. Job's Syndrome: Recurrent, "cold", staphylococcal abscesses. The Lancet. 1966;1(7445):1013–1015. DOI: 10.1016/S0140-6736(66)90119-X. PMID: 4161105.

  2. Buckley RH, Wray BB, Belmaker EZ. Extreme hyperimmunoglobulinemia E and undue susceptibility to infection. Pediatrics. 1972;49(1):59–70. PMID: 5007042.

  3. Holland SM, DeLeo FR, Elloumi HZ, et al. STAT3 mutations in the hyper-IgE syndrome. New England Journal of Medicine. 2007;357(16):1608–1619. DOI: 10.1056/NEJMoa073687. PMID: 17881745.

  4. Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007;448(7157):1058–1062. DOI: 10.1038/nature06096. PMID: 17728758.

  5. Zhang Q, Davis JC, Lamborn IT, et al. Combined immunodeficiency associated with DOCK8 mutations. New England Journal of Medicine. 2009;361(21):2046–2055. DOI: 10.1056/NEJMoa0905506. PMID: 19776401.

  6. Grimbacher B, Holland SM, Gallin JI, et al. Hyper-IgE syndrome with recurrent infections—an autosomal dominant multisystem disorder. New England Journal of Medicine. 1999;340(9):692–702. DOI: 10.1056/NEJM199903043400904. PMID: 10053178.

  7. Chandesris MO, Melki I, Natividad A, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore). 2012;91(4):e1–19. DOI: 10.1097/MD.0b013e31825f95b9. PMID: 22706353.

  8. Gatz SA, Benninghoff U, Schütz C, et al. Curative treatment of autosomal-recessive hyper-IgE syndrome by hematopoietic cell transplantation. Bone Marrow Transplantation. 2011;46(4):552–556. DOI: 10.1038/bmt.2010.151. PMID: 20562920.

  9. Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. Journal of Clinical Immunology. 2018;38(1):96–128. DOI: 10.1007/s10875-017-0464-9. PMID: 29226301.

  10. Freeman AF, Holland SM. The hyper IgE syndromes. Immunology and Allergy Clinics of North America. 2008;28(2):277–291. DOI: 10.1016/j.iac.2008.01.008. PMID: 18424333.